BRANSON, Mo. - TelAve -- Metavalis Inc, a strategic bioengineering firm situated at the intersection of synthetic biology and national defense, today announced the appointment of Aman Khera, EMBA, FRAPS, FTOPRA, as the first official member of its Scientific Advisory Board (SAB). Khera will serve as the company's Regulatory Science, Innovation, and Compliance Advisor.

This appointment signals a critical maturation in the Metavalis operational strategy. As the company advances its dual use pipeline comprising of The Stealth LNP therapeutic platform and the Project Omega neural interface it requires a regulatory architecture as advanced as its technology.

Khera, widely recognized in the life sciences industry as the "Rebel Regulator," brings nearly three decades of global leadership experience. She is a Fellow of both the Regulatory Affairs Professionals Society (FRAPS) and The Organisation for Professionals in Regulatory Affairs (FTOPRA) the highest credentials in the field.

More on TelAve News

• eJoule Inc Participates in Silicon Dragon CES 2026
• HBZBZL Unveils "Intelligent Ecosystem" Strategy: Integrating AI Analytics with Web3 Incubation
• Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
• A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
• Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas

"We are building something at Metavalis that does not fit into a standard regulatory box," stated Jordan Bekemeier, Founder of Metavalis Inc. "When you are architecting re-dosable genetic medicines and solid-state neural preservation systems, you cannot rely on the old guard of regulatory thinking. You need someone who understands the rules well enough to rewrite them for the future. You need a Rebel."

Aman Khera will lead the regulatory strategy for:

The "Lumina" Program: Navigating the expedited pathways for the company's lead orphan drug asset for Crigler-Najjar Syndrome Type 1.

The Cardinal Physics Kernel: Establishing the compliance framework for the company's proprietary AI and physics based simulation environments.

Digital Health Integration: Leveraging her expertise at the intersection of Healthcare, AI, and Digital Health to bridge the gap between biological and optical computing.

"We didn't choose Aman just for her formidable resume, we chose her because she runs toward the future while others shy away from it," Bekemeier added. "Her mission is to ensure innovation actually reaches the people who need it. That aligns perfectly with our Warrior Ethos."

More on TelAve News

• Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
• Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
• Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
• Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
• Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026

About Aman Khera Aman Khera is a globally recognized regulatory strategist, patient champion, and PharmaVoice 100 Honoree. With a career spanning nearly 30 years, she has guided complex therapeutics from early strategy to commercialization. She is a pragmatic strategist known for challenging conventional norms to accelerate patient access to life saving innovations.

Check Out What We Are Building At

https://metavalis.com/

Check Us Out On Crunchbase At

https://www.crunchbase.com/organization/metavalis